Form 4: Amicus Therapeutics CPO Sells Shares for Tax

Amicus Therapeutics' Chief People Officer, David Michael Clark, reported the sale of 23,879 shares of common stock at $14.27 per share to cover tax liabilities.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, Inc. (FOLD), reported two transactions involving the disposition of common stock.
• On January 2, 2026, 5,381 shares of common stock were disposed of at a price of $14.27 per share.
• On January 3, 2026, an additional 18,498 shares of common stock were disposed of at a price of $14.27 per share.
• These transactions, totaling 23,879 shares, were coded "F," indicating they were for the payment of exercise price or tax liability incident to the receipt, exercise, or vesting of a security.
• Following these transactions, David Michael Clark beneficially owns 221,811 shares of Amicus Therapeutics common stock directly.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, signifying pre-planned sales.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-planned sales by an executive to cover tax liabilities, which is a neutral event and does not indicate any significant positive or negative sentiment regarding the company's prospects.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction for a specific company executive and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, particularly for tax purposes under a 10b5-1 plan, is generally viewed as a neutral event and is unlikely to have a significant direct impact on shareholder value or perception.

Key Dates

Recommendation

The reported transactions are routine sales by an executive to cover tax obligations, executed under a pre-arranged 10b5-1 plan. Such transactions are not indicative of a change in the company's fundamentals or the executive's long-term view, and therefore do not warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Amicus Therapeutics, FOLD, David Michael Clark, Chief People Officer, Insider Trading, Form 4, Stock Sale, Tax Liability, Rule 10b5-1